en · de · es · pt
cardarine-notes.peptides6608.com › News › Identity And Pharmacological Mechanism — Explained

Identity And Pharmacological Mechanism — Explained

By Editorial Desk · published 2025-08-07 · last reviewed 2025-08-26 · News

Prohibited list raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-08-26. Anything still debated is marked as such rather than presented as settled.

Identity and Pharmacological Mechanism

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Preclinical Findings and Safety Signals

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Cardarine at a glance

PropertyValueNotes
Chemical classSynthetic PPARδ agonistNot a steroid or a selective androgen receptor modulator.
Common synonymsCardarine, GW501516, GW-501516, endurobolNames vary by supplier and literature source.
AppearanceWhite to off-white powderConsistent with many small-molecule research chemicals.
SolubilityLow in water; soluble in DMSO and ethanolOften prepared in organic solvent for laboratory work.
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid and energy metabolism.

Detection and Regulatory Landscape

Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.

Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.

A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.

Related pages on this site

Identity and Regulatory Status

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Mechanism and Research Context

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

Notes from published material

=== Random selenomethionine === In addition, selenium occurs in proteins as nonspecifically incorporated selenomethionine, which replaces methionine residues. Proteins containing such nonspecifically incorporated selenomethionine residues are not regarded as selenoproteins, as the incorporation of selenium is not required for any function of the protein. In bacteria, the replacement of methionine by selenomethionine is mostly tolerated. In animals, an excess amount of selenomethionine replacement results in "alkali disease" affecting the structure of keratin and other tissue proteins. This is a major mechanism of selenium toxicity in animals. The nonspecific incorporation and the relative tolerance of bacteria to selenomethionine substitution has been used to determine the structure of proteins. A protein is produced with all methionines replaced by selenomethionines via expression in a microorganism grown in selenomethionine. This allows the use of MAD-phasing during X-ray crystallographic structure determination of many proteins.

== Philosophy, origins, architects == The international drug conventions occurred within the newly formed United Nations, as the UN assumed the duties of the retired League of Nations after WWII. The preamble to the Single Convention establishes the overarching concern of the drug treaties as "the health and welfare of mankind". It recognizes "narcotic drugs" as "indispensable for the relief of pain and suffering" and that they "must be made [available] for such purposes". It also recognizes addiction to narcotics as "a serious evil for the individual and is fraught with social and economic danger to mankind" and that there is a duty of nations to "prevent and combat this evil". The conventions offer a degree of interpretative flexibility within a framework of control through prohibition. Controlled substances used for medical and scientific purposes are regulated, while other uses are prohibited; "each of the treaties encourages – and often requires – that member countries put in place strong domestic penal provisions." A report by the Library of Parliament for the government of Canada on the history of the conventions identifies four themes as critical influences on the nature of the treaties: prohibition, United States involvement, external influences, and the outsized impact of certain powerful individuals. Prohibition of illicit use, "as opposed to regulation", has been the central philosophy. The US has been "the key player in most multilateral negotiations" and the prohibitionist approach "derives largely from U.S.

George Charles Eltenton (14 April 1905 – 26 April 1991) was an English physicist, specialising in chemical physics and a pioneer of mass spectrometry. He was a Fellow of the Physical Society. He and his wife were suspected of being agents of the USSR looking for US atom bomb secrets. He was named by Robert Oppenheimer when interviewed by the Atomic Energy Commission which resulted in Oppenheimer being stripped of his security clearance, in the so-called Chevalier Incident.

The adsorption/desorption processes of a permeant's molecule normally exhibit a linear dependency with the partial pressure gradient across the barrier layer, while keeping the assumption of steady-state transport conditions and exhibiting a concentration lower than the penetrant's maximum solubility, thereby adhering to Henry's law of solubility. The type of permeant, the barrier layer's thickness, the specific permeabilities of the packaging films against gases or vapors, the packaging's permeable area, the temperature, and the pressure or concentration gradient between the barrier's interior and external sides can all have an impact on a system's permeability. The gas exchange occurring between the packaging system and the external environment has a significant impact on the quality and safety of food products. Uncontrolled physico-chemical and biological processes, such as oxidation of vitamins, excessive microbial growth, and spoilage of the packed food, may lead to improper conditions inside the packaging headspace, hence reducing their shelf-life. Therefore, the packaging system should be designed to create the ideal conditions for the selected product, avoiding excessive gas exchange. Among the permeants that could affect the organoleptic properties of food, oxygen and water vapor represent the most important ones.

Sources: en.wikipedia.org

Further detail

== Clinical significance == Band neutrophils are an intermediary step prior to the complete maturation of segmented neutrophils. Polymorphonuclear neutrophils are initially released from the bone marrow as band cells. As the immature neutrophils become activated or exposed to pathogens, their nucleus will take on a segmented appearance. An increase in the number of these immature neutrophils in circulation can be indicative of an infection for which they are being called to fight against, or some inflammatory process. The increase of band cells in the circulation is called bandemia and is a "left shift" process. Blood reference ranges for neutrophilic band cells in adults are 3 to 5% of white blood cells, or up to 0.7 billion/L. An excess may sometimes be referred to as bandemia.

. Aston's early model of nuclear structure (prior to the discovery of the neutron) postulated that the electromagnetic fields of closely packed protons and electrons in the nucleus would interfere and a fraction of the mass would be destroyed. A low packing fraction is indicative of a stable nucleus.

Bromperidol decanoate, sold under the brand names Bromidol Depot, Bromodol Decanoato, and Impromen Decanoas, is an antipsychotic which has been marketed in Europe and Latin America. It is an antipsychotic ester and long-acting prodrug of bromperidol which is administered by depot intramuscular injection once every 4 weeks.

Sources: en.wikipedia.org

Supporting material

EF-P (elongation factor P) is an essential protein that in bacteria stimulates the formation of the first peptide bonds in protein synthesis. Studies show that EF-P prevents ribosomes from stalling during the synthesis of proteins containing consecutive prolines. EF-P binds to a site located between the binding site for the peptidyl tRNA (P site) and the exiting tRNA (E site). It spans both ribosomal subunits with its amino-terminal domain positioned adjacent to the aminoacyl acceptor stem and its carboxyl-terminal domain positioned next to the anticodon stem-loop of the P site-bound initiator tRNA. The EF-P protein shape and size is very similar to a tRNA and interacts with the ribosome via the exit "E" site on the 30S subunit and the peptidyl-transferase center (PTC) of the 50S subunit. EF-P is a translation aspect of an unknown function, therefore It probably functions indirectly by altering the affinity of the ribosome for aminoacyl-tRNA, thus increasing their reactivity as acceptors for peptidyl transferase. EF-P consists of three domains:

For example, SEC-MALS analysis of a monodisperse protein will show that the entire peak consists of molecules with the same molar mass, something that is not possible with standard SEC analysis. Determination of molar mass with SLS requires combining the light scattering measurements with concentration measurements. Therefore SEC-MALS typically includes the light scattering detector and either a differential refractometer or UV/Vis absorbance detector. In addition, MALS determines the rms radius Rg of molecules above a certain size limit, typically 10 nm. SEC-MALS can therefore analyze the conformation of polymers via the relationship of molar mass to Rg. For smaller molecules, either DLS or, more commonly, a differential viscometer is added to determine hydrodynamic radius and evaluate molecular conformation in the same manner. In SEC-DLS, the sizes of the macromolecules are measured as they elute into the flow cell of the DLS instrument from the size exclusion column set. The hydrodynamic size of the molecules or particles are measured and not their molecular weights. For proteins a Mark-Houwink type of calculation can be used to estimate the molecular weight from the hydrodynamic size. A major advantage of DLS coupled with SEC is the ability to obtain enhanced DLS resolution. Batch DLS is quick and simple and provides a direct measure of the average size, but the baseline resolution of DLS is a ratio of 3:1 in diameter. Using SEC, the proteins and protein oligomers are separated, allowing oligomeric resolution. Aggregation studies can also be done using ASEC.

=== Acute treatment === Acute treatments are most effective when administered early in an attack. Initial recommended treatment for acute mild to moderate attacks is with over-the-counter (OTC) medications such as ibuprofen (Advil, Motrin) and paracetamol (acetaminophen, Tylenol) for pain. Triptans are recommended as a first-line therapy for moderate to severe attacks. The approval of CGRP inhibitors (gepants) is seen as a major advance in migraine treatment. Anti-nausea medications are used as a second-line treatment for migraine-related nausea. Ergotamines may be used by those experiencing headaches that do not respond to over-the-counter pain medications. Opioids should not be prescribed, as higher doses of opioids are linked to medication overuse headache (MOH) and increased risk of progression from episodic to chronic migraines. MOH can also be caused by frequent use of simple pain relievers such as paracetamol (more than 15 days a month), or by the use of triptans for more than 10 days a month. The UK National Institute for Care and Health Excellence recommends an abrupt pause of one month in the use of triptans and simple pain relievers in case of MOH; this may lead to a short-term increase in symptoms. Corticosteroids such as dexamethasone have been used to treat patients with an attack lasting more than three days, severe baseline disability, or refractory or recurrent headaches. Systematic review and network meta-analysis have been used to compare the effectiveness of medications for acute migraine attacks in adults.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.

How does cardarine interact with the body?

It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.

Is cardarine found naturally?

No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Network